Vivos Therapeutics Targets $3.6M in Annual Savings Amid Revenue Growth Push

  • Vivos Therapeutics expects to save $3.6M annually starting Q4 2026 through restructuring, including staff reductions and vendor changes.
  • Referrals to Las Vegas Sleep and Airway Medicine Centers surged 3-fold from June to September 2026, with revenue impact expected in Q4 2026.
  • EEG diagnostic testing initiative projects $1.5M–$3.0M annualized run rate by Q4 2026, while RPM program aims for $3.5M annualized revenue by Q1 2027.
  • Legacy payer contract renegotiations could add $2.4M–$5.6M in revenue, with full realization expected by early 2027.

Vivos Therapeutics is aggressively restructuring to cut costs while expanding revenue streams, a strategic pivot aimed at addressing the undiagnosed OSA market. The company's focus on AI-driven IT systems and renegotiating payer contracts reflects broader industry trends toward operational efficiency and value-based care. Success hinges on executing these initiatives without disrupting core operations or patient care.

Cost Reduction Execution
Whether Vivos can fully realize the $3.6M in annual savings without operational disruptions or unforeseen transition costs.
Revenue Growth Sustainability
The pace at which patient referrals and new initiatives like EEG testing and RPM can sustain revenue growth into 2027.
Cash Flow Positive Timeline
How quickly Vivos can achieve cash flow positivity by late 2026 or early 2027, given the combined impact of cost cuts and revenue initiatives.